Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You got that right!!
2004?????? That was 7 years ago, bud.
Incorrect. There wasn't a 'ton' of volume in the sub pennies. Honest question: Are you new to trading?
WNRC-- .10 was the key resistance. Looks thin to the high teens.
Thanks for the kind words.
WNRC ~ .125 Two year highs.
I agree, does look stronger. 20% a day isn't bad.
WNRC ~ .12
WNRC- .12 Past major resistance. Worth a look here, obi.
Looks like another leg starting. Looking good.
WNRC .11
You got that right! They have put a TON of work in the last 8 months.
MCET Share Structure
Per latest 10Q
AS:775,000,000
OS:434,728,911
Float: 313,000,000
MCET- .0099 Breakout watch
That's a good start. I'd add in MCET
and WNRC. Both will be nice gainers this week.
{MCET Grant news}
MultiCell Technologies Receives $733,437 Cash Grant Award Under U.S. Government's Qualifying Therapeutic Discovery Project Program
Press Release Source: MultiCell Technologies, Inc. On Tuesday November 2, 2010, 8:00 am EDT
WOONSOCKET, R.I., Nov. 2, 2010 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board:MCET.OB.ob - News) announces it has received cash grant awards under the U.S. government's Qualifying Therapeutic Discovery Project ("QTDP") program. The QTDP program was created by Congress as part of the Patient Protection and Affordable Care Act, and provides a tax credit or grant equal to eligible costs and expenses for tax years 2009 and 2010.
To be eligible, a therapeutic development project must: (i) have the potential to develop new treatments that address "unmet medical needs" or chronic and acute diseases; (ii) reduce long-term health care costs; (iii) represent a significant advance in finding a cure for cancer; (iv) advance U.S. competitiveness in the fields of life, biological, and medical sciences; or (v) create or sustain well-paying jobs, either directly or indirectly.
"We are pleased our MCT-465 and MCT-475 drug development programs for the treatment of cancer, and our MCT-125 drug development for the treatment of fatigue in multiple sclerosis patients qualified for certification under the QTDP program," stated W. Gerald Newmin, Chairman and CEO of MultiCell. "For our programs where we requested certification, a combined total of $1,466,875 was certified as qualifying expenses under the QTDP program, and of that amount, $733,437 was awarded to MultiCell as a cash grant," Mr. Newmin further stated. The QTDP grant awards are not taxable for U.S. federal income tax purposes, but may be taxable for State income tax purposes.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools to address unmet medical needs for treatment of neurological disorders, hepatic disease and cancer.
MultiCell's therapeutic development platform relies on patented techniques to: (i) isolate, characterize and differentiate stem cells from the human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin treatment, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.
MultiCell's drug candidates are in various stages of discovery optimization, and preclinical and clinical development:
* MCT-125 is a Phase 2 therapeutic candidate for treatment of fatigue in MS patients, which has demonstrated efficacy in a 138-patient Phase IIa clinical trial.
* MCT-465 is a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
* MCT-475 is a discovery stage antibody therapeutic candidate for use in combination with dsRNA for the treatment of solid tumor cancers.
* MCT-485 is a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.
For more information about MultiCell Technologies, please visit http://www.multicelltech.com.
{MCET Share Structure}
Per latest 10Q
AS:775,000,000
OS:434,728,911
Float: 313,000,000
***Important Repost***
Nina4900 Member Profile Nina4900 Member Level Share Thursday, August 26, 2010 7:41:36 PM
Re: None Post # of 2450
Just listened in on today's special shareholders meeting chaired by Jerry Newmin. All proposals passed, and more shares were authorized for LaJolla Cove funding and employee/other incentive deals. Jerry said La Jolla has provided $2-1/2 mil of the $10 mil they promised.
Really sounds to me like they have a solid plan underway to survive in these hard times for finding funding, until they see about the hopeful awarding of grants, financing deals, and getting MCT-125 through trials so they can sell it and move on to many more candidates.
Jerry's highlights:
* He reviewed the various patents awarded
* They hired the clinical group for MCT-125 trials in the UK
* Work with Maxim Biotech is progressing, and they expect to roll out product by end of this year
* Continuing use of the cells for more research
* Special mention of the 3 cancer drug candidates - I'm glad these are back on front burner
* Market cap has been up, daily trading volume up
* Applied for 4 grants, 3 cancer drugs and the MCT-125, that would fill "large unmet needs" - "Grants would give us the ability to proceed without more dilution." This is great if they can get them. Jerry said they expect to find out later this year.
* New website is up
* Jerry discussed expenses, but all I had notes on were the monies spent to protect intellectual property, can't remember the rest, but we know they are very conservative and targeted about spending only the most necessary money.
* Debt is down, cash position is up
* They are launching an e-commerce website by 4Q '10 or 1Q '11 to sell products and generate revenue. This was exciting to hear. Initially it will be done with Maxim Biosciences and offer products for drug target discovery. They will focus on oncology related product.
* Jerry said "We're looking good for the future." I think so, as this sounds like a new MCET moving out on several fronts to find revenue while they get the job done.
Questions:
* An email question asked about time frames and path to FDA approval and Jerry offered the quote, "10 years a $1 billion to get one drug to market." He said MCT-125 has Phase llb data, so it's further along, and they will concentrate on this. He said 2-5 years to do this in UK. One of the other board members said expect 5 years at the earliest once they are funded, to see if successful and ask for approval. (I thought it would be 2-3 years, so personally disappointed at that update, but I know they don't want to be overly optimistic publicly.) It was mentioned by Jerry or one of the other board member that they already have MHRA (Medicines and Healthcare Products Regulatory Agency) approval in the UK so they can go ahead. That was good news. They are still looking for partners.
* A caller asked about whether they were still considering ventures or a buyout to expand potential and the board member said he could not talk about it but they are always looking. That was interesting...
* Caller asked for more info on the products - rental or sale? - and board member said all consumable life science reagent tool kits. Maybe in future go with something like instrument company with leasing basis. But they are obviously focusing on all the constant consumable product they can hustle. He said the are developing "recurring revenue streams and new streams with Maxim Bioscience and others." I like the addition of "others" smile. He used the term "synergistic products."
(I would suggest looking at what Dr. Chang did with Stemgent, his company, and you can see where I think he's heading MCET, while they work diligently for funding and keep up the research. Just Google the company and you'll get the picture: http://www.stemgent.com/commerce/pages/home ,
http://www.xconomy.com/boston/2009/03/09/stemgent-nails-down-14m-to-make-supplies-tools-for-stem-cell-researchers/ ,
http://www.masshightech.com/stories/2010/05/17/daily5-Stem-cell-RD-firm-Stemgent-takes-in-56M.html ,
http://www.businesswire.com/news/home/20100415006837/en/Stemgent-Pfizer-Announce-Collaboration
No more questions so the meeting was over quickly.
Perhaps some sort of meeting notes will appear via IR soon. I know I probably missed some info, so maybe someone else here recorded the meeting and can fill in.
All in all I'm pleased, and will keep digging in the couch for funds to buy as I can. This company continues to show amazing determination to survive and push forward. They keep dotting i's and crossing t's. It's gone on a lot longer than I ever imagined, having started accumulating stock in 2001, but I will look forward to watching MCET develop along this new and broader path to success.
GLTA
Nina
Hasn't been a pr since october, bud.
A quick phone call to AVTC could easily settle these arguments. {eom}
Welcome onboard, buzz.
Yup, we are here and on MCET. What's on your mind?
Good idea...or find someone with half decent writing skills and post an article on TheStreet.com & SeekingAlpha.com. Savvy investors deserve to hear the {WNRC} story, licker4450.
{WNRC--Video of Studio Tour}
20,000 square feet
{WNRC--Video of Studio Tour}
20,000 square feet
100% gain in last couple weeks impresses me!!
WNRC is starting to wake up...a sleeping giant, if you will.
WNRC~ Possibly the tightest float of all the Teffy's Tight Float Plays, at 13M.
WNRC Share Structure as of 1/19/2011
Confirmed with TA
AS: 100,000,000
OS: 38,786,542
Float: 13,846,490
MCET ~.0079 Breakout watch
MCET ~ .0072
We need one lucky person to step up and buy 100,000 shares at the ask and send this one. It would be a nice position in a fast growing, undervalued company.
MCET~ Worth a look here.
Nice blocks going off at the ask here.